Skip to main content
Caplight Logo









Qkine

Qkine

Private
CambridgeHealthcare & Life Scienceshttps://qkine.com/

Last Round

VC Round

Mar 21, 2025

Total Funding Raised

$3.15M

Company Overview

Qkine is a biotechnology company that manufactures high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell and organoid culture.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

recombinant proteinsgrowth factorsanimal-free reagentscell therapy reagentsbioprocessingGMP reagentsstem cell researchcytokinesorganoid developmentgood manufacturing practiceGMPbiomanufacturinglab reagentsbiotech supply chaincustom protein production

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Qkine Comparables

Compare Qkine with similar companies based on industry and business-model similarity.

Qkine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ORF Genetics
81%
Core Biogenesis
80%
Akron Biotech
78%

Qkine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 21, 2025
DebtDec 19, 2022
VC RoundDec 15, 2022
Series AJun 8, 2020
SeedJun 3, 2019
Seed
Apr 23, 2018

Qkine Investors

Notable investors and investment history

Qkine investors
InvestorRounds
Innovate UKDebt
o2h venturesVC Round
Cambridge EnterpriseSeed, Series A
Downing VenturesVC Round
Parkwalk AdvisorsVC Round, Series A
Oxford Innovation FinanceVC Round
Martlet CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    Launched QkPlate (C), pre-prepared dried vitronectin-coated plates.

  • Mar 23, 2026

    Developing QkPlate (C) human vitronectin coated plates.

Recent news

Latest coverage and updates

  • partners_withJun 22, 2026

    Qkine Ltd partnered with Defined Bioscience, Inc. on May 1st '26.

Qkine Filings

Explore SEC and related filing metadata, where available.

Qkine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Qkine's valuation, stock price, and market status.

Is Qkine a public or private company?

Qkine is a private company.

What is the current stock price of Qkine?

Qkine is a private company with no public stock price. No recent secondary market data is available.

How much is Qkine worth (valuation)?

Valuation information for Qkine is not publicly available.

Can I buy Qkine stock?

Qkine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Qkine's last funding round?

Qkine's most recent funding round was Debt on December 19, 2022.

Who are the main investors in Qkine?

Key investors in Qkine include Cambridge Enterprise, Downing Ventures, Parkwalk Advisors.

Will Qkine IPO soon?

No public IPO plans have been announced for Qkine.

How can I track Qkine secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Qkine's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range29
Year Founded2016
Last FundingMar 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?